A study of the hematopoietic and iron metabolism effect of epoetin beta pegol on non-dialysis chronic kidney disease patients who do not respond well to darbepoetin alfa by monitoring hepcidin-25.

A study of the hematopoietic and iron metabolism effect of epoetin beta pegol on non-dialysis chronic kidney disease patients who do not respond well to darbepoetin alfa by monitoring hepcidin-25. - A study of the hematopoietic and iron metabolism effect of epoetin beta pegol on non-dialysis chronic kidney disease patients who do not respond well to darbepoetin alfa by monitoring hepcidin-25.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009658

Enrollment

Registered

2013-02-01

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-dialysis chronic kidney disease

Interventions

darbepoetin alfa epoetin beta pegol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients of filling the following all criteria and having ability for agreement 1)The patients diagnosed of renal anemia ,administrated darbepoetin alfa for more than six months and less than 11g/dl hemoglobin.

Exclusion criteria

Exclusion criteria: the patients having allergy for epoetin beta pegol ,erythropoietin and darbepoetin alfa the patients of gastrointestinal hemorrhage the patients having or had liver damages

Design outcomes

Primary

Measure	Time frame
Percentage of maintaining the target Hb level	—

Countries

Japan

Contacts

Public Contactkiyoto koibuchi

Saiseikai yokohama-city tobu hospital nephrology

buchi500@msn.com045-576-3000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026